Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT)

Cameron frames N,N-dimethyltryptamine (DMT) as a historically used, chemically simple but pharmacologically important indole-containing psychedelic. The introduction reviews its long-standing use in South American religious preparations such as ayahuasca, notes that DMT produces intense hallucinogenic effects at modest doses (historically cited above 0.2 mg/kg), and highlights its ubiquity in plants and animals as well as its status as one of the few psychedelics produced endogenously in mammals. The author emphasises that while ayahuasca has been associated with antidepressant and anxiolytic effects, regulatory restrictions on DMT (Schedule I in many jurisdictions) have constrained research. This review sets out to collate and synthesise knowledge about DMT, covering its biosynthesis and chemical synthesis, pharmacology and receptor binding, metabolism and pharmacokinetics, adverse effects, evidence for endogenous production, psychoplastogenic properties, and potential medical applications. Cameron also intends to place DMT in a historical context within chemical neuroscience and to identify remaining questions about its physiological roles and therapeutic promise.

The paper is a narrative review rather than a systematic review; the extracted text does not report a formal search strategy, inclusion criteria, or meta-analytic methods. Instead, the author organises the material thematically into sections on synthesis (biosynthetic and chemical), pharmacodynamics, metabolism and pharmacokinetics, adverse effects, endogenous production, potential medical use, and the compound's history and importance to neuroscience. Cameron draws on a mixture of historical reports, in vitro and in vivo pharmacology, animal behavioural studies, human pharmacokinetic and clinical observations, and recent mechanistic work on neural plasticity. Where available, quantitative data (for example, receptor affinities, pharmacokinetic time courses, and toxicology estimates) are reported from the primary literature; however, the review does not present new experimental data or pooled statistical analyses.

Synthesis: DMT is produced biosynthetically by methylation of tryptamine via indolethylamine N-methyltransferase (INMT) with S-adenosylmethionine as methyl donor; a second methylation yields DMT. Chemists commonly prepare DMT by reductive amination of tryptamine (tryptamine + formaldehyde + sodium cyanoborohydride) with yields reported around 70%, or by a three-step Speeter–Anthony type acylation/reduction sequence, the latter having been used to make material for human studies. Practical notes on purification are provided: the free base is typically extracted into organic solvents and purified by sublimation or salt formation (fumarate is recommended for storage), and DMT should be stored cold and dark to avoid decomposition. Pharmacodynamics: Unmetabolised DMT binds a broad array of targets, with nanomolar affinities reported for multiple serotonin receptors (including 5-HT1A, 5-HT2A and 5-HT2C among others). Agonism at 5-HT2A is emphasised as the principal mediator of interoceptive and hallucinogenic effects and is also implicated in DMT's psychoplastogenic actions: DMT increases dendritic complexity and spine density in cortical neurons via an mTOR-dependent mechanism that involves 5-HT2A activation, and ketanserin blocks these structural effects. The molecule also acts as an agonist at 5-HT1A (reported affinity ~183 nM), which may contribute anxiolytic/antidepressant actions through somatodendritic autoreceptor modulation. Other targets include sigma-1 receptors (DMT is an endogenous sigma-1 agonist with Kd ≈ 15 μM, substantially weaker than its 5-HT2A affinity), TAAR1 activation, substrate-like interactions with SERT and VMAT2, and relatively weak dopamine receptor binding (Ki ≈ 5 μM). The review notes limited characterisation of interactions with 5-HT1D, 5-HT6 and 5-HT7 receptors and little work on cholinergic effects beyond modest regional changes in acetylcholine. Behavioural pharmacology: In rodents, DMT produces a 5-HT2A-dependent head-twitch response that is strain-dependent in mice, and elicits serotonin-syndrome-like motor effects in rats shortly after administration. Acute dosing often causes transient anxiogenic and motor effects (reduced exploration, altered locomotion), but an acute hallucinogenic dose (example given 10 mg/kg in rats) also facilitates cued fear extinction and produces antidepressant-like responses in the forced swim test comparable to ketamine. The author links these behavioural outcomes to synaptic and dendritic plasticity in the prefrontal cortex, which may persist after drug clearance. Metabolism and pharmacokinetics: DMT has a rapid onset and short subjective duration in humans when given intravenously or smoked, with peak effects reported at about 5 minutes and most effects ceasing by ~30 minutes. Measured blood and urine concentrations of injected DMT are low (examples: 1.8% and 0.16% of dose detectable at any time, as reported), and a high brain:plasma ratio (approximately 2–6) is established rapidly with greatest accumulation in cortex and amygdala in rats. The compound is rapidly metabolised by MAO-A and liver enzymes; in vivo half-life is given as ~5–15 minutes and can be extended by MAO inhibition. Oral inactivity of DMT reflects first-pass MAO-A degradation, which is overcome in ayahuasca preparations by coadministered β-carboline MAO inhibitors such as harmine and harmaline. Major metabolites listed include indoleacetic acid, DMT-N-oxide, N-methyltryptamine, and several tetrahydro-β-carbolines. Adverse effects and safety: Common acute physical effects include nausea, vomiting and transient increases in heart rate, blood pressure and temperature. Rodent-derived LD50 estimates cited are approximately 1.6 mg/kg (intravenous) and 8 mg/kg (oral), though these derive from animal data. Psychologically, DMT can cause short-term distress and, rarely, precipitate persistent psychosis in individuals with predisposing conditions; the review stresses such long-term adverse psychiatric outcomes are exceptional and often associated with polysubstance abuse or prior vulnerability. Religious ayahuasca-using populations have not shown increased prevalence of schizophrenia, and some long-term users report improved psychological wellbeing. The author reiterates that DMT and ayahuasca do not appear to promote compulsive drug-seeking and are generally considered non-addictive relative to substances such as alcohol or nicotine. Endogenous production: Multiple lines of evidence are summarised supporting endogenous DMT synthesis in mammals and humans. INMT is expressed across tissues, most highly in lung, and homologues exist across species; early measurement concerns have been addressed by modern LC-MS/MS methods confirming trace levels in body fluids and tissue. Microdialysis detected DMT in rat pineal gland, though the capacity of the pineal to produce hallucinogenic quantities is questioned; the lungs are suggested as a more plausible peripheral source given high vascularisation and INMT expression. Product inhibition of INMT by DMT itself and generally low concentrations make it uncertain whether endogenous DMT reaches levels required for hallucinatory states, but subhallucinogenic concentrations may still influence neural plasticity. Some preliminary and historical data hint that stress may elevate endogenous DMT, and developmental roles are proposed because INMT activity appears higher perinatally. Potential therapeutic use: Much clinical evidence for therapeutic effects comes from ayahuasca studies, which have reported antidepressant, anxiolytic and anti-addictive effects in humans and animals. Harmine and other β-carbolines likely contribute to ayahuasca's actions beyond simply increasing oral DMT bioavailability. There are no reported human clinical trials of DMT administered alone for mood or anxiety disorders in the extracted text, though preclinical data indicate that DMT alone can produce antidepressant-like effects, enhance fear extinction, and promote neural plasticity. Additionally, DMT and 5‑MeO‑DMT show anti-inflammatory properties via sigma-1 receptor activation, reducing pro-inflammatory cytokines and increasing IL-10, suggesting a potential avenue for neurodegenerative and inflammatory conditions.

Cameron interprets DMT as a deceptively simple molecule that occupies a central place in serotonergic psychedelic pharmacology and neuroscience. The review emphasises that despite its small size and simple structure, DMT binds multiple receptor systems and produces robust structural and functional neural plasticity, effects that may underlie observed antidepressant and anxiolytic outcomes in animal models and in ayahuasca studies. The author highlights the dual importance of DMT as both a scaffold for many indole psychedelics and as a probe for understanding how receptor agonism (notably at 5-HT2A and possibly sigma-1) can drive rapid changes in dendritic and synaptic architecture. At the same time, significant uncertainties are acknowledged. Cameron notes the lack of human clinical trials testing DMT in isolation, variability in ayahuasca composition and preparation, and difficulties in measuring and interpreting endogenous DMT levels and their physiological significance. Regulatory constraints (Schedule I status) are cited as historical and ongoing barriers that have slowed research, though the author points to a resurgence of interest since the 1990s and argues for more mechanistic, developmental, and clinical work. Specific priorities identified include determining whether endogenous DMT is produced in sufficient quantities to affect brain function, clarifying receptor-specific contributions to behavioural and plasticity effects, and conducting controlled clinical studies to assess therapeutic efficacy and safety of DMT-containing interventions.